[on oligozoospermia and asthenospermia]

Zhonghua Nan Ke Xue. 2020 Jun;26(6):543-546.
[Article in Chinese]

Abstract

Objective: To observe the clinical effect of Yihechun Capsules (YHC) on oligozoospermia and asthenospermia.

Methods: A total of 181 male patients with infertility were randomly divided into a YHC+Levocarnitine (LC) group (n = 93, including 42 cases of oligozoospermia, 20 cases of asthenospermia and 31 cases of oligoasthenospermia) and an LC control group (n = 88, including 39 cases of oligozoospermia, 22 cases of asthenospermia and 27 cases of oligoasthenospermia), the former treated with YHC ([0.3 g per capsule], once 4 capsules, bid, 30 minutes after meal) combined with LC oral liquid (2-3 g/d, tid, at mealtime) and the latter with LC oral liquid only (2-3 g/d, tid, at mealtime). After 3 months of treatment, comparisons were made between the two groups of patients in sperm concentration, the percentages of grade a and grade a+b sperm, and the rate of pregnancy.

Results: Of the 181 patients, 5 in the YHC+LC group and 2 in the LC control group failed to complete the course of treatment. There were no statistically significant differences between the two groups of patients in the baseline sperm concentration and the percentages of grade a and grade a+b sperm (P > 0.05), wich were all markedly increased in both the YHC+LC and the LC control groups (P < 0.05) after 3 months of treatment. And the patients of the YHC+LC group, compared with the controls, showed even more significant increases, as the oligozoospermia patients in sperm concentration ([21.07 ± 6.98] vs [16.56 ± 1.82] ×10⁶/ml, P < 0.05) and the percentages of grade a sperm ([27.53 ± 3.34]% vs [26.88 ± 1.35]%, P < 0.05) and grade a+b sperm ([53.32 ± 3.16]% vs [52.63 ± 2.48]%, P < 0.05), the asthenospermia patients in sperm concentration ([26.36 ± 3.37] vs [24.42 ± 2.21] ×10⁶/ml, P < 0.05) and the percentages of grade a sperm ([25.28 ± 4.64]% vs [21.32 ± 3.28]%, P < 0.05) and grade a+b sperm ([49.19 ± 2.87]% vs [45.64 ± 1.78]%, P < 0.05), and the oligoasthenospermia patients in sperm concentration ([19.38 ± 3.39] vs [18.75 ± 1.35] ×10⁶/ml, P < 0.05) and the percentages of grade a sperm ([22.65 ± 4.81]% vs [21.31 ± 2.42]%, P < 0.05) and grade a+b sperm ([48.74 ± 5.61]% vs [44.36 ± 1.32]%, P < 0.05). The pregnancy rate was dramatically higher in the YHC+LC than in the LC control group (36.4% [32/88] vs 15.1% [13/86], P < 0.01).

Conclusions: Yihechun Capsules combined with Levocarnitine oral liquid is evidently effective for the treatment of oligozoospermia and asthenospermia.

Keywords: Yihechun Capsules; asthenospermia; clinical effect; oligoasthenospermia; oligospermia.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Asthenozoospermia / drug therapy*
  • Carnitine / therapeutic use*
  • Drugs, Chinese Herbal / therapeutic use*
  • Female
  • Humans
  • Male
  • Oligospermia / drug therapy*
  • Pregnancy
  • Pregnancy Rate
  • Sperm Count
  • Sperm Motility
  • Spermatozoa

Substances

  • Drugs, Chinese Herbal
  • Carnitine